- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model. NEW YORK ( TheStreet) -- Onyx Pharmaceuticals (Nasdaq: ONXX) hit a new 52-week high Tuesday as it is currently trading at $91.46, above its previous 52-week high of $91.42 with 928,082 shares traded as of 4 p.m. ET. Average volume has been 1.5 million shares over the past 30 days. Onyx has a market cap of $5.8 billion and is part of the health care sector and drugs industry. Shares are up 102.1% year to date as of the close of trading on Monday. Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. The company has a P/E ratio of 307.1, above the average drugs industry P/E ratio of 296.9 and above the S&P 500 P/E ratio of 17.7.